Switch theme
Sign up to access all valuation multiples
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.
1990
225
LTM Revenue $155M
LTM EBITDA $51.4M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioGaia has a last 12-month revenue (LTM) of $155M and a last 12-month EBITDA of $51.4M.
In the most recent fiscal year, BioGaia achieved revenue of $150M and an EBITDA of $50.1M.
BioGaia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioGaia valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $155M | XXX | $150M | XXX | XXX | XXX |
| Gross Profit | $113M | XXX | $109M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $51.4M | XXX | $50.1M | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBIT | $48.6M | XXX | $43.2M | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 29% | XXX | XXX | XXX |
| Net Profit | $38.5M | XXX | $37.1M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 25% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 1, 2025, BioGaia's stock price is SEK 106 (or $11).
BioGaia has current market cap of SEK 10.7B (or $1.1B), and EV of SEK 9.5B (or $1.0B).
See BioGaia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.1B | XXX | XXX | XXX | XXX | $0.41 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 1, 2025, BioGaia has market cap of $1.1B and EV of $1.0B.
BioGaia's trades at 6.7x EV/Revenue multiple, and 20.0x EV/EBITDA.
Equity research analysts estimate BioGaia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioGaia has a P/E ratio of 29.4x.
See valuation multiples for BioGaia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBITDA | 19.5x | XXX | 20.0x | XXX | XXX | XXX |
| EV/EBIT | 20.6x | XXX | 23.2x | XXX | XXX | XXX |
| EV/Gross Profit | 8.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.4x | XXX | 30.6x | XXX | XXX | XXX |
| EV/FCF | 26.7x | XXX | 26.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioGaia's last 12 month revenue growth is 8%
BioGaia's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.
BioGaia's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioGaia's rule of X is 54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioGaia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 47% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioGaia acquired XXX companies to date.
Last acquisition by BioGaia was XXXXXXXX, XXXXX XXXXX XXXXXX . BioGaia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BioGaia founded? | BioGaia was founded in 1990. |
| Where is BioGaia headquartered? | BioGaia is headquartered in Sweden. |
| How many employees does BioGaia have? | As of today, BioGaia has 225 employees. |
| Who is the CEO of BioGaia? | BioGaia's CEO is Ms. Theresa Agnew. |
| Is BioGaia publicy listed? | Yes, BioGaia is a public company listed on STO. |
| What is the stock symbol of BioGaia? | BioGaia trades under BIOG B ticker. |
| When did BioGaia go public? | BioGaia went public in 1998. |
| Who are competitors of BioGaia? | Similar companies to BioGaia include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of BioGaia? | BioGaia's current market cap is $1.1B |
| What is the current revenue of BioGaia? | BioGaia's last 12 months revenue is $155M. |
| What is the current revenue growth of BioGaia? | BioGaia revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of BioGaia? | Current revenue multiple of BioGaia is 6.5x. |
| Is BioGaia profitable? | Yes, BioGaia is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioGaia? | BioGaia's last 12 months EBITDA is $51.4M. |
| What is BioGaia's EBITDA margin? | BioGaia's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of BioGaia? | Current EBITDA multiple of BioGaia is 19.5x. |
| What is the current FCF of BioGaia? | BioGaia's last 12 months FCF is $37.6M. |
| What is BioGaia's FCF margin? | BioGaia's last 12 months FCF margin is 24%. |
| What is the current EV/FCF multiple of BioGaia? | Current FCF multiple of BioGaia is 26.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
